John Crowley, BIO CEO
April 2, 2025 11:49 AM EDT
People
Pharma
FDA+

Q&A: John Crow­ley warns biotech is 'dan­ger­ous­ly close' to break­ing, as tar­iff threat, mar­kets bat­ter in­dus­try

Max Bayer

Pharma Reporter

John Crow­ley is clear-eyed about the ob­sta­cles he faces. As CEO of the trade group BIO, he’s been tasked with mount­ing a po­lit­i­cal come­back for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Cor­rect­ed: Trump's broad tar­iffs could mark a 'dou­ble wham­my' for phar­ma af­ter FDA cuts

Chaot­ic tar­iff roll­out leaves as many ques­tions as an­swers for drug­mak­ers

Sarep­ta, Roche pause Ele­v­idys tri­als in Eu­rope fol­low­ing pa­tient death

Day af­ter mass FDA fir­ings, new com­mis­sion­er ad­dress­es re­main­ing staff, fo­cus­ing on 'MA­HA' vi­sion

FDA cuts stir buy­er’s re­morse for some bio­phar­ma lead­ers, once ex­cit­ed by Trump

sponsored

End­points we­bi­nar: In­side the “One Lon­za” strat­e­gy: Re-en­gi­neer­ing the fu­ture of CD­MO

A service from the Financial Times